<DOC>
	<DOCNO>NCT01521611</DOCNO>
	<brief_summary>To determine whether radiolabelled antibody target bone marrow ( 'anti-CD66 ' ) administer safely patient part preparative treatment prior haematopoietic stem cell transplantation ( ' bone marrow transplant ' ) . Can radiolabelled antibody show effectively target bone marrow patient . If , could result good outcome transplantation .</brief_summary>
	<brief_title>Targeted Radiotherapy HSCT Poor Risk Haematological Malignancy</brief_title>
	<detailed_description>The aim clinical research study establish whether radiolabelled antibody use safely deliver radiotherapy bone marrow prior stem cell transplantation haematological malignancy . With current chemotherapy regimens 60-90 % adult patient acute leukaemia ( AML ALL ) achieve complete remission . However significant proportion patient disease recur . Although allogeneic autologous bone marrow peripheral blood haematopoietic stem cell transplantation ( HSCT ) establish effective treatment option haematological malignancy , result long term disease free survival significant proportion patient , result transplantation patient poor risk disease disappoint . Further intensification treatment use prior transplantation show reduce risk relapse , toxicity drug external beam radiotherapy cause increase transplant related death . The introduction reduce intensity conditioning protocol allow use HSCT old patient significant additional medical problem retrospective analysis indicates increase rate relapse . This 'Transplantation dilemma ' - reduce risk disease relapse intensify therapy , without increase toxicity organs cause increase transplant related death remission . Normal haematopoietic tissue malignant cell arise radiosensitive . Theoretically intensification condition therapy , particularly total body irradiation ( TBI ) , prior transplantation could increase tumour reduction lead improved disease free survival rate patient poor risk disease . Targeted radiotherapy could allow treatment intensification without toxicity non-haematological tissue . In addition , continuous , low dose rate deliver natural decay target radionuclide may great destructive effect upon tumour cell single dose fractionated external beam radiation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . An underlying haematological malignancy include acute myeloid leukaemia first complete remission ( CR1 ) poor prognostic feature &gt; CR1 relapse ; acute lymphoblastic leukaemia ; transform myelodysplasia , chronic myeloid leukaemia ( accelerated phase blast transformation , poor response intolerance tyrosine kinase inhibitor ) , myeloma . Patients may remission , partial remission relapse . 2 . No concurrent recent ( within 3 week ) chemotherapy underlie haematological condition 3 . For patient relapsed leukaemia , BM blast must represent &lt; 20 % BM nucleate cell . 4 . Although BM remission status important , patient must cellularity &gt; 10 % . 5 . As malignant plasma cell may may express CD66 antigen , patient myeloma must less 30 % plasma cell ( percentage total nucleated cell ) BM time study . 6 . Age = &gt; 18 yr . 7. WHO performance status 0 , 1 2 ( Appendix 5 ) . 8 . Predicted lifeexpectancy great four month . 9 . Patients must negative human antimouse antibody ( HAMA ) . 10 . Peripheral blood count : Wbc &lt; 30 x 10e9/l ( absolute neutrophil count &gt; 0.5 x 10e9/L ) platelet &gt; 50 x 10e9/l ( platelet support permit ) 11 . Biochemical index : Plasma creatinine &lt; 120 micromol/l ( creatinine clearance EDTA clearance &gt; 50 ml/min ) Plasma bilirubin &lt; 30 micromol/l Aspartate aminotransferase ( AST ) Alanine aminiotransferase ( ALT ) 2.5 x upper limit normal range . 12 . Patient must able provide write informed consent . 1 . Any serious intercurrent disease . 2 . Patients BM cellularity &lt; 10 % . 3 . History atopic asthma , eczema allergy rodent protein , confirm history severe allergic reaction penicillin streptomycin . 4 . Positive HAMA . 5 . Patients unable provide inform consent unable cooperate reason poor mental physical health . 6 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Transplant</keyword>
	<keyword>BMT</keyword>
	<keyword>yttrium</keyword>
	<keyword>indium</keyword>
</DOC>